Skip to main content
Boston Scientific’s family of CRT devices


Our focus

Transforming lives with comprehensive solutions to support kidney stone removal, prostate health, erectile restoration and urinary continence.

Dr. Siegel’s story

We provide solutions for use during the treatment of kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction, male incontinence and pelvic floor disorders.

Delivering meaningful innovation

Advancing kidney stone management.

Boston Scientific conducted research around the world to study how flexible ureteroscopy and percutaneous nephrolithotomy procedures are being conducted and how they can be improved. This research indicated that retrieving kidney stones is one of the most time-consuming steps during ureteroscopy procedures. Based off these findings, Boston Scientific concluded urologic surgeons would value increased surgeon control during this step of the procedure and limited effort required to coordinate people, tools and movements.*

Expanding options for addressing prostate health.

Boston Scientific has a growing portfolio of products that may impact the quality of life and clinical outcomes for people with prostate cancer and benign prostatic hyperplasia (BPH).

check icon

In one study evaluating Rezūm™ Water Vapor Therapy, patients experienced significant improvements of BPH symptoms sustained through 5 years of follow-up.¹

check icon

The SpaceOAR™ Hydrogel is used by physicians at 10 of the top 10 U.S. cancer centers in 2023.²

check icon

Designed for satisfaction as a long-term treatment option for erectile dysfunction, more than 500K AMS 700™ Inflatable Penile Prostheses have been sold worldwide.²

Some conditions our customers manage:

  • Kidney Stones
  • Benign Prostatic Hyperplasia (BPH)
  • Prostate Cancer
  • Erectile Dysfunction
  • Pelvic Floor Disorders (Stress Urinary Incontinence and Pelvic Organ Prolapse)
  • Male Incontinence


of the population worldwide affected by kidney stone disease.3


of U.S. men affected by benign prostatic hyperplasia by age 60.4


of every 10 U.S. men, it is estimated, will suffer from erectile dysfunction (ED) during their lifetime.5


U.S. women, it is estimated, experience involuntary leakage of urine.6

Please see footnotes for detailed study data.

Focus areas

  • Stone Management Solutions 
  • BPH Treatment Options
  • Hydrogel Perirectal Spacer Placed Prior to Prostate Cancer Radiation Therapy
  • Penile Implants for Erectile Dysfunction
  • Urinary Control Systems for Male Stress Urinary Incontinence
  • Mid-Urethral Slings and Urethral Bulking Agent for Female Stress Urinary Incontinence

Product spotlights


  1. McVary KT, Gittelman MC, Goldberg KA. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urology. 2021 Sep;206(3):715-724.
  2. Data on file at Boston Scientific. 
  3. Alelign T, Petros B. Kidney stone disease: An update on current concepts. Adv Urol. 2018 Feb 4;3068365.
  4. Barry M, Roehrborn C. Management of benign prostatic hyperplasia. Annu Rev Med. 1997 Feb;48:177-89. 
  5. Erectile Dysfunction. Accessed on 5/23/2023.
  6. Wu JM, Hundley AF, Fulton RG, et al. Forecasting the prevalence of pelvic floor disorders in U.S. women: 2010 to 2050. Obstet Gynecol. 2009 Dec;114(6):1278-83.
  7. Ibrahim A, Elhilali MM, Fahmy N, et al. Double-blinded prospective randomized clinical trial comparing regular and Moses modes of holmium laser lithotripsy. J Endourol. 2020 May;34(5):624-8.
  8. Whiles BB, Martin AJ, Brevik A, et al. Utilization of Moses modulated pulse mode results in improved efficiency in holmium: YAG laser ablation of the prostate. Urology. 2021 Mar;149:18792.
  9. Kavoussi NL, Nimmagadda N, Robles J, et al. MOSES technology for holmium laser enucleation of the prostate: A prospective double‐blind randomized control trial. J Urol. 2021 Jul;206(1):104-8.
  10. Armstrong N, et al. SpaceOAR Hydrogel Spacer for Reducing Radiation Toxicity During Radiotherapy for Prostate Cancer. A Systematic Review. Urology. 2021 Oct;156:e74-e85. doi: 10.1016/j.urology.2021.05.013. Epub 2021 May 23. PMID: 34029607.
  11. Mynderse L A, Hanson D, Robb R et al. Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. J Urology. 2015 Jul;86(1):122-7.

*Market research study sponsored by Boston Scientific. Data on file.

Boston Scientific acquired the global surgical business of Lumenis Ltd. Lumenis Pulse™ 120H is the registered product name. Lumenis Pulse™ 120H with MOSES Technology is manufactured and sold by Boston Scientific. Lumenis is a registered trademark of Lumenis Be.

Rx Only

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a physician.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.